Quick Answer
Inhibitor Therapeutics, Inc. reported Stockholders Equity of -$1.29 million for fiscal year 2025.
Inhibitor Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | -$1.29M | -165.1% |
| 2024 | $1.99M | -62.4% |
| 2023 | $5.28M | -36.3% |
| 2022 | $8.30M | +329.1% |
| 2021 | -$3.62M | -7.8% |
| 2020 | -$3.36M | -32.8% |
| 2019 | -$2.53M | -7924.0% |
| 2018 | $32.4K | -80.6% |
| 2017 | $166.6K | -97.6% |
| 2016 | $7.03M | +1558.1% |
| 2015 | $424.0K | +583.0% |
| 2014 | $62.1K | +108.1% |
| 2013 | -$765.8K | -476.8% |
| 2012 | -$132.8K | +64.0% |
| 2011 | -$369.1K | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $3.5K | -99.9% | -99.5% |
| June 30, 2025 | $715.6K | -82.7% | -47.1% |
| March 31, 2025 | $1.35M | -70.8% | -31.9% |
| December 31, 2024 | $1.99M | -62.4% | -41.7% |
| September 30, 2024 | $3.41M | -47.2% | -17.7% |
| June 30, 2024 | $4.14M | -41.8% | -10.8% |
| March 31, 2024 | $4.64M | -40.2% | -12.2% |
| December 31, 2023 | $5.28M | -36.3% | -18.1% |
- Inhibitor Therapeutics, Inc. showed a decrease of -165.1% in Stockholders Equity compared to the prior fiscal year.
- Over the 2011–2025 period, Inhibitor Therapeutics, Inc.’s stockholders equity has declined by 250.0% (from -$369.1 thousand to -$1.29 million).
- The most recent figure is from Inhibitor Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: